Droia Ventures — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)Josh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Board seatJanwillem Naesens· per SEC Form D
Frontier Meds develops small-molecule drugs targeting previously undruggable protein targets using a proprietary approach to identify and exploit novel binding sites across the human proteome.
BiotechSouth San Francisco, US
Jim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)Cameron Wheeler(Director)Gregory Chow(Executive Officer)Chris Varma, Ph.D.(Executive Officer, Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.